Qi Biodesign, a Beijing, China-based biotechnology firm pioneering next-generation genome enhancing applied sciences, accomplished its Sequence A funding spherical.
The Sequence A spherical was led by the Beijing Medical and Well being Care Business Funding Fund (Restricted Partnership), with extra investments from Beijing Changping Expertise Innodevelop Group, Mingzhe Capital, and returning investor CD Capital. Earlier traders additionally embrace Apricot Capital, Supply Code Capital, Gaorong Ventures, CSSD Capital, Shang Capital, and CASSTAR.
The corporate has now raised a complete of $75m throughout its Seed, Sequence Pre-A, and Sequence A phases.
The newly secured funding will likely be used to boost Qi Biodesign’s R&D capabilities, advance its proprietary SEEDIT™ platform, assist its product improvement and construct commercialization platforms to streamline and velocity up the transition from analysis to market.
Qi Biodesign was based in 2021 by main genome enhancing scientists Dr. Caixia Gao and Dr. Kevin Zhao (Chief Expertise Officer), and trade specialists Dr. Bei Zhang (Chief Government Officer), and Haiquan Yang (Chief Enterprise Officer). Qi Biodesign has established itself as a frontrunner in genomic innovation with its proprietary SEEDIT™ analysis platform, that includes superior genome enhancing instruments corresponding to novel RNA-guided nucleases, base editors, plant prime editors, and PrimeRoot™ editors for exact giant DNA insertions and manipulations. These applied sciences allow multiplex gene enhancing, fine-tuning of gene expression, and high-throughput trait discovery, driving the event of superior organic traits to deal with world challenges in crop breeding and artificial biology.
Qi Biodesign has already achieved vital milestones in product improvement, together with receiving two biosafety certificates for gene-edited vegetation (excessive oleic acid soybean and powdery mildew disease-resistant wheat) by the China Ministry of Agriculture and Rural Affairs and securing an exemption for a gene-edited product (excessive oleic acid soybean) from the US Division of Agriculture. Extra gene-edited traits together with yield enhancements, herbicide tolerance and high quality enhancements are advancing via regulatory pipelines. Qi Biodesign’s plant breeding improvements advance the appliance of gene enhancing in agriculture, contributing to meals safety and sustainable developments.
FinSMEs
06/12/2024
